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This study was a project within the German Research Foundation (DFG) collaborate research 
center (CRC) 1112 studying nanocarrier (NC) for topical application of drugs for their 
therapeutic use in inflammatory skin diseases like psoriasis and atopic dermatitis.  
Topical treatment of skin diseases may have many advantages over systemic treatment: 1) 
high drug concentrations at the site of action, 2) less exposure of non-target organs to the drug 
and therefore less systemic side effects and 3) less loss of drug due to metabolism in the liver 
and other organs. Compared to injections, it is less invasive, painless, and more convenient 
for the patients. However, topical treatment is also challenging: most importantly, the skin is a 
very effective barrier, which prevents penetration of a large proportion of otherwise effective 
drugs. In addition, compared to injection or oral uptake, a topically applied drug typically has 
relatively little time for sufficient penetration due to mechanical removal and eventual shedding 
by desquamation. Furthermore, there is low patient compliance with sticky ointments that are 
still needed to formulate lipophilic drugs.  
Psoriasis is a common human skin disease, which is incurable and therefore requires lifelong 
therapy.1 The easily visible skin lesions decrease the quality of life and patients often suffer 
from depression.2 Available topical creams or ointments are sticky and have to be applied 
frequently. Furthermore, systemic therapy with immunomodulatory drugs is often required to 
control severe cases but possesses a high risk for undesired side effects.1,3 Thus, treatment 
of psoriasis would profit from improved systems for topical drug delivery and was chosen by 
the CRC 1112 as one of the two model diseases.  
One system that has been proposed to improve topical delivery are NC, where small molecules 
may incorporate drugs and enable or increase the penetration of drugs or establish a drug 
depot, minimizing further distribution and systemic side effects. Ideally, they may even deliver 
their cargo exclusively into diseased skin to the site of action. Thereby the NC could have a 
therapeutic surplus value by successful topical treatment, targeted to the diseased areas with 
decreased systemic side effects. In the context of the CRC 1112, several different NC were 
developed to tackle this task.  
The aim of this project was to evaluate the most advanced NC developed within the CRC 1112, 
the core-multishell-nanocarrier (CMS), on healthy murine skin and a mouse model of psoriasis 
in vivo. Emphasis was placed on local or systemic effects and skin penetration behavior of the 
carriers themselves, as well as enhancement of cargo drug delivery for a therapeutic surplus 
value against standard formulations. 
Simultaneously, within the CRC the same particles were also investigated in vivo in a mouse 
model of atopic dermatitis by Radbruch et al. (2017).4 In addition, collaborating groups of the 
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CRC developed various further NC, which were tested in different models, including excised 
human skin, pig ear skin, as well as in cell culture and reconstructed skin models. 
1.1 Skin – background 
Skin architecture 
From outside to inside, the skin is composed of a stratum corneum, a viable epidermis, both 
belonging to the epidermis, a basement membrane, and the dermis and is connected via the 
subcutis to the underlying tissue.  
The epidermis is composed of four basic layers: the stratum corneum, stratum granulosum, 
stratum spinosum, and stratum basale. The latter three represent the viable epidermis.  
The stratum corneum, the outermost layer, fulfills the main barrier function.5 It is composed of 
very flat, non-nucleated keratinized keratinocytes, the corneocytes. Their intracellular protein 
keratin is partially responsible for the toughness of the skin.6 Multiple lamellar lipid bilayers 
surround the cells in addition to their cell membranes filling the spaces in between. The lipid 
composition of these bilayers differs markedly from regular cell membranes and plays a role 
in barrier function. They contain gycosyl-ceramides, cholesterol, cholesterol-esters, and long-
chain fatty acids.6 
The keratinocytes of the underlying viable epidermis are tightly connected via desmosomes 
and tight junctions.7 These keratinocytes originate from basal cells in the stratum basale, the 
innermost epidermal layer. These germinal cells proliferate to renew the epithelium 
continuously. On their way to the surface, the cells differentiate to the progressively flattening 
keratinocytes through the stratum spinosum and stratum granulosum and finally lose their 
nucleus and become keratinized in the stratum corneum before they are shed.6 
Approximately 3-5 % of the nucleated cells in the epidermis are Langerhans cells, the specific 
local dendritic cells.8 The cell body is preferably located suprabasilar but their long dendrites 
extend up beneath the stratum corneum,9 where they take up and process microbial and non-
microbial antigens. By secreting cytokines, they contribute to the innate immunity but they are 
also important for the adaptive immunity by migrating to the regional lymph node and 
presenting antigens to lymphocytes.7 
Epidermis and dermis are divided by a basement membrane, which forms a barrier and 
scaffold for the overlying basal cells.  
The underlying dermis contains abundant extracellular matrix molecules produced by 
fibroblasts forming a mesh important for mechanical strength, elasticity, and resistance to 
compression and cell anchoring.7 In addition, nerves, blood, and lymph vessels as well as 
immune cells such as mast cells, lymphocytes, plasma cells, and dermal dendritic cells are 
found in the dermis.6,7 
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Skin adnexa include hair follicles with their musculi arrectores pilorum, sweat, and sebaceous 
glands, contributing to the skin barrier against mechanical injury and playing a role in body 
temperature homeostasis.6 
Barrier function 
The skin shields the body effectively from mechanical and physical injuries as well as infectious 
agents but also constitutes a barrier for topically applied drugs or NC. This barrier function is 
achieved by an interplay of several physical, biochemical, and immunological elements. 
The stratum corneum with its multilayer lipid extracellular matrix seems to be the most 
important barrier for water, hydrophilic substances, and particles. The tight junctions between 
the viable keratinocytes serve as important barrier as well.10,11 The next mechanical barrier is 
the tight mesh of the basement membrane. 
Besides being a mechanical barrier, the stratum corneum also forms a redox barrier with 
buffering sulfur-rich layers12 and vitamin E in sebaceous gland secretions protecting against 
antioxidant injury.6 Acids contributing to an average skin surface pH of below 5 as well as 
lysozymes and antimicrobial peptides or defensins protect to a certain extent against 
microorganisms.10,13 
However, the skin surface environment also favors colonization of certain microorganisms. 
This microbiome also prevents colonization of potentially harmful microorganisms by 
competing symbiotic, normally harmless bacteria and fungi for space and nutrition on the skin 
surface. Furthermore, the microbiome is in close contact and interferes with the immune 
system.7 
The immune system also plays an important role in the skin’s barrier function with immune 
cells within the skin. Especially Langerhans cells in the epidermis build an immunologic first 
line of defense as explained above (see 1.1 Skin – background; Skin architecture). In addition, 
keratinocytes secreting chemokines attracting other immune cells to a site of injury, contribute 
to the immune barrier against infectious agents.7 
Murine skin versus human skin  
In this study, mice were used because of the availability for in vivo studies, the option to model 
an inflamed skin, and the possibility of histologic examination of organs after experiments on 
whole organisms in contrast to ex vivo skin models. The mouse is a widely used model in 
research but one has to keep in mind that there are differences in human and murine skin, 
which can also influence study outcomes regarding skin penetration behavior and immune 
responses. Histologically visible differences include a thinner skin, with a 29 µm thick epidermis 
in mice versus a 47 µm thick epidermis in humans and a 9 µm thick stratum corneum in mice 
versus a 17 µm thick stratum corneum in humans, depending on the body region.14 This can 
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lead to a weaker skin barrier in penetration studies depending on the examined substance.14 
Furthermore, commonly used mouse strains express a close coat compared to sparse hair in 
most human body regions, which complicates topical applications. Sweat glands are only 
found in footpads in mice and all over the body in humans.15 These differences influence the 
choice of models and have to be balanced to practicability. The results have to be compared 
or controlled between species or mouse strains. 
Skin barrier disruption  
In penetration studies of drugs or nanoparticles (NP), skin barrier disruption is important to 
consider. Slight skin barrier disruptions can easily occur, for example, after scratching.16,17 In 
inflammatory skin diseases, changes in epidermal thickness, metabolic capacity, 
microstructure of the stratum corneum, and larger surface integrity can lead to barrier 
disruptions.18 An impaired barrier function can lead to increased penetration;19 this can be 
intentional in topical therapy targeting only diseased skin regions, but can also be unintentional 
making barrier disruption models essential in toxicological examinations. In research, several 
models for skin barrier disruptions have been developed to mimic diseased skin for penetration 
studies including chemical, mechanical, or inflammatory approaches.  
For example, chemical irritants, also used in certain pharmacologic topical formulations as 
penetration enhancers, temporarily impair the skin barrier to facilitate drug penetration. 
Mechanical injury of the stratum corneum is often used in ex vivo but also in in vivo studies, 
especially via tape stripping, where superficial layers of the stratum corneum are removed by 
adhesive tape. Simple techniques like massaging can increase penetration by hair movement 
pumping into hair follicles.20 
1.2 Psoriasis – a common inflammatory skin disease in humans 
The CRC 1112 used psoriasis as a prototype of a common, immune mediated human skin 
inflammation1 with impaired barrier, which may result in increased penetration of some NP.21 
On the other hand, barrier alterations could also lead to less penetration of substances, for 
example, by thickening of viable epidermis and stratum corneum.22  
Epidemiology and symptoms of psoriasis 
Psoriasis has a prevalence of 3 % in the adult population,23 equally in both sexes, with a 
bimodal onset of 16-22 or 57-60 years of age.3 
Well-demarcated, erythematous plaques covered with silver scales are preferably found on 
the scalp, trunk, buttocks and extremities of the patients with plaque type psoriasis.3 
Histologically these changes are based on a hyperproliferative epidermis with premature and 
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incompletely cornified keratinocytes.3 Other forms of psoriasis, including psoriasis arthritis, are 
of lesser importance for this study.  
Pathogenesis of psoriasis 
Psoriasis is a multifactorial disease associated with genetic predispositions, epigenetic 
variations, a dysregulated immune system including autoantigens, and influencing 
environmental factors.3,24,25 
Psoriasis related genes are mostly linked to the innate and adaptive immune system.26 About 
half of the genetic variations are connected to major histocompatibility complexes, but over 70 
other loci have been identified including nuclear factor κβ, Interferons (IFN) or interleukin (IL) 
23 signaling.1 
Environmental factors such as trauma can trigger psoriasis. The trauma initiates typical 
psoriasis immune signaling pathways by triggering keratinocytes to release antimicrobial 
peptides like LL37, whose complexes with DNA or RNA bind to toll-like receptors (TLR).26 
Thereby plasmacytoid and myeloid dendritic cells are activated, secreting IFN α and β, 
activating more myeloid dendritic cells.26 Psoriasis specific cytokines are produced, IL 12 and 
IL 23 activate T-helper 17, 1, and 22 lymphocytes, which produce IL 17 A and F, IL 22, IL 21, 
and IL 36.26 This culminates in proliferating keratinocytes with increased chemokine production 
and immune cell infiltration in dermis and epidermis.26 LL37 is also an autoantigen in some 
psoriasis patients where recognition by circulating LL37-specific T lymphocytes leads to IL 17 
production.26 Tumor necrosis factor (TNF) α and IFN γ, released by T-helper 1 lymphocytes, 
also activate keratinocytes to proliferate and produce cytokines and antimicrobial peptides.26  
Reduced microbiome diversity and altered composition have been identified in patients and 
inappropriate immune responses against microbiota may lead to lesion maintenance or 
induction.26  
Psoriasis pathogenesis has intensively been studied revealing many aspects, but the complete 
pathogenesis is still not fully understood. 
Barrier alteration in psoriasis 
In psoriasis, a combination of primary and secondary barrier alterations are suggested.27 
Primary skin barrier dysfunction results from genetic alterations in genes encoding proteins 
important for barrier function, mostly components of corneocytes, intercellular lipids, or cell 
interconnection in the stratum corneum. Deletions in late corniﬁed envelope (LCE) genes 
LCE3B and LCE3C, for example, lead to impaired corneocyte differentiation.28  
Barrier dysfunction is also in part secondary to immune reactions taking place in psoriatic skin. 
Enzyme release from leukocytes, for example, can degrade structural elements or infiltrating 
leukocytes can actively disconnect tight junctions to migrate into the viable epidermis.  
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For many reported changes regarding barrier function, it is unclear whether they reflect primary 
or secondary changes including altered lipid composition or decreased expression of the tight 
junction protein zonulin 1.29–31 
It remains unclear if the sum of all alterations of the barrier, including in psoriasis, increases or 
decreases the penetrability for NC or drugs. For the drug tacrolimus (TAC) for example, it is 
suspected that severe thickening of the epidermis and hyperkeratosis of thick psoriasis 
plaques hinders TAC penetration and thus its efficacy.22 This assumption is supported by the 
fact that TAC alleviates facial psoriasis, which exhibits thinner epidermis.22 
Standard therapy of psoriasis 
Although there is no cure for psoriasis, various treatment options are available and have been 
complemented by new therapies in recent years. Mono treatments or combinations of topical 
or systemic immunomodulatory drugs, such as methotrexate, phototherapy, or biologicals, 
including etanacept, can be administered.1,3  
These immunomodulatory drugs are effective but can have severe side effects, especially the 
systemic administered agents can lead to chronic injury of organs biotransforming or excreting 
these drugs, such as the liver or kidney, or via immunosuppression to infections. However, 
long-term topical corticoid therapy can also lead to allergy, skin atrophy, or increased 
susceptibility to skin infection.32 
Mouse model used in this study: the imiquimod–induced psoriasis-like dermatitis model 
Since psoriasis does not occur in species other than humans, there is a need for animal models 
in research. Several genetically engineered, xenograft and drug- induced models have been 
developed, but models only resemble some aspects of a real disease.33 It is important to use 
a model meeting all the requirements needed for the hypothesis in question. 
In this study, the imiquimod (IMQ)-induced mouse model was used to mimic psoriasis in mice. 
This model is relatively inexpensive and easy to induce by topical application of IMQ every day 
on the skin of the mouse. By choosing the area of application, the later inflamed area can be 
limited to minimize the stress for the mice. 
IMQ is a toll-like receptor 7 and 8 agonist used in topical treatment of human genital warts and 
some skin tumors like basal cell carcinoma.34 In psoriasis patients, the usage of this drug was 
found to trigger the formation of psoriasis plaques and repeated application on the skin of 
healthy mice lead to skin lesions similar to psoriasis.35 
Morphologic changes resemble those observed in human psoriasis including hyperkeratosis, 
erythema, scaling, micro abscesses, and infiltration by γδ T cells and T helper 17 
lymphocytes.36 The IMQ-induced psoriasis model also depends on immune pathways shown 
to be crucial in human psoriasis including IL 22, IL 36 and the IL 23-IL 17 axis.26,36 
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An elevated transepidermal water loss (TEWL) reflects inside-out barrier disruption in this 
mouse model. Increased drug penetration and thus outside-in disruption was also shown. 
Decreased amounts of β-catenin and involucrin, important proteins in cell to cell interactions 
via desmosomes, have been described and could add to this barrier weakening.37 
The IMQ-induced psoriasis-like mouse model has intensively been used in different studies 
focusing on human psoriasis pathogenesis as well as in penetration studies and drug efficacy 
studies because of good pathologic, clinic, and histologic resemblance to the human disease. 
However, the model’s response to anti-psoriatic drugs is not sufficiently studied. 
1.3 Tacrolimus – a drug with challenging skin penetration properties 
TAC is a macrolide calcineurin inhibitor and is described to be roughly 100 times more potent 
than cyclosporine A.38 TAC is immunosuppressive by decreasing transcription of cytokines 
important for T cell function.  
This drug is used systemically after organ transplantations but also topically applied 
formulations are available for the treatment of inflammatory skin diseases like atopic 
dermatitis.39  
In psoriasis, TAC has only been shown to be effective in thin skin regions like the face but not 
on thick psoriasis plaques.22 It is suggested that its high lipophilicity and high molecular weight  
of 822.05 Dalton hinders the penetration through thick psoriasis plaques.40  
Therefore, TAC is used as a prototype high molecular weight drug, studied in the CRC 1112 
whose field of application could be widened if NC could achieve an increased delivery into the 
skin.   
1.4 Nanomaterial and nanocarrier 
Nanoparticles, from “nanos” for “dwarf” in Greek, are small particles with a diameter of at least 
one dimension of 1 nm up to 100 nm.41,42 Because of their high surface to volume ratio, they 
exhibit different physicochemical properties compared to their bulk materials.42,43 For example, 
quantum effects between the surface and the surrouding molecules may start to have a 
proportionally larger effect.  
Engineered NP are widely used in technology, for example surface coatings, titanium dioxide 
in sunscreen, or bacteriostatic silver NP used in bandages or to prevent odor in socks.44,45 NP 





Nanocarrier - dermal drug delivery concept 
NC are an innovative approach to carry a cargo drug with otherwise suboptimal 
pharmacokinetic properties to its site of action. In the skin, such a system could mean a 
tremendous advantage, as most drug formulations based on passive delivery via the skin are 
typically limited to lipophilic drugs with a molecular weight < 500 Dalton.47 For each NC, a 
therapeutic surplus in comparison to standard formulations of drugs has to be shown to 
legitimize the more expensive production of a medication. This benefit could be achieved by 
different properties:  
The nanoparticulate properties could increase drug penetration through skin. For tacrolimus-
loaded lipid NP, for example, an increased skin penetration, skin accumulation, and 
bioavailability was shown compared to reference drugs.48,49 NC could even achieve a targeted 
delivery by restricted penetration into barrier disrupted, inflamed skin areas50 or accumulation 
of NC in a specific skin layer with ongoing cargo release from that region.51 This could also 
reduce undesired local and systemic side effects by minimizing drug distribution to irrelevant 
tissues. For example, corticosteroids can locally induce dermal atrophy by inhibiting collagen 
synthesis or osteoporosis if they are distributed to bones.52,53 
NC could also protect sensitive drugs on their way to the site of release and action by 
encapsulation. Alternatively, they can simply be used to give a proper solubility of an otherwise 
poorly soluble compound in a more convenient topical substrate, like lipophilic drugs in 
hydrogels, which are more convenient to use for patients compared to sticky ointments. 
Nanoparticle toxicology  
Besides the therapeutic surplus, biocompatibility of the NC also has to be proven before further 
development of NC for the use in patients.  
Unintended NP, for example in exhaust fumes, ashes, and dust formed in fires or volcano 
eruptions, are thought to be a threat mainly to the respiratory system because of deep 
inhalation of particles smaller than 2 µm into the lung alveoli where they are phagocytosed by 
macrophages.6 However, topical skin contact is also thought to constitute a potential risk. It 
was shown that people chronically walking barefoot on volcanic dust can develop podoconiosis 
with severe lymphedema in limbs due to NP accumulation and induction of lymphangitis.42 
For intentionally synthetic NC it is therefore important to exclude toxic or negative effects. Even 
topically applied NP may penetrate through the skin and reach distant sites in the body via the 
bloodstream, inducing intended or unintended effects.54 
For example, 70 nm amorphous silica NP were reported to penetrate the skin and were found 




Nanocarrier used in this study: core-multishell-nanocarrier  
Architecture of core-multishell-nanocarrier 
Dendritic hPG-amid-C18-mPEG core-multishell-nanocarrier are constructed as a copolymer 
and have an approximate diameter of 16 nm.4,56–59 They contain a hydrophilic hyperbranched 
polyglycerol (hPG) core, to which amphiphilic side chains are covalently bound via amid 
bonds.4,56–59 The side chains form an inner lipophilic shell with a C18H36 saturated carbohydrate 
chain (C18) and an outer hydrophilic shell of monomethyl polyethylene glycol (mPEG) around 
the core.4,56–59 The design resembles a liposome being able to incoorporate different cargos in 
the different shells. In contrast to a liposome, the single molecule architecture is less prone to 
destruction by shear force.4,56–59  
Penetration behavior of and cargo delivery by core-multishell-nanocarrier ex vivo and in vivo  
Previous to the study in this thesis (see paper 1 at 2.1), the penetration behavior of CMS had 
only been investigated in vitro and ex vivo. CMS did not penetrate into intact reconstructed 
human skin in vitro or human and porcine skin ex vivo.60,61 In contrast, NC penetration was 
observed after prolonged exposure on ex vivo human skin, as well as usage of a non-
melanoma skin cancer reconstructed model. Mechanical barrier disruption by tape-stripping of 
human ex vivo skin also resulted in CMS penetration.60 
Furtermore, CMS was shown to increase cargo delivery of nile red (NR) into epidermis and 
dermis of intact human skin and porcine ear skin ex vivo.60,61  
Simultaneously to the study in this thesis (see paper 1 at 2.1), also within the CRC 1112, the 
CMS were examined in vivo in an oxazolone-induced mouse model of atopic dermatitis.4 No 
penetration into viable layers of the skin in intact as well as barrier altered inflamed mouse skin 
was shown.4 No systemic distribution was observed following topical application and no 
adverse effects of the NC was observed locally in the skin or systemically, even after 




1.5 Scientific questions and hypotheses 
1.5.1  Do CMS show any unintended local or systemic effects after topical application on 
healthy or inflamed psoriasis-like murine skin? 
Negative effects of the NC are not expected since available toxicological data to this particle 
and closely related NC do not show adverse effects in vitro.4,62 (See also toxicological data in 
paper 1 at 2.1) 
1.5.2  Do CMS penetrate into healthy murine skin and if they do, to what extent and how 
deep? 
It is not expected that CMS penetrate into intact murine skin because in vitro studies using 
reconstructed human skin showed only penetration after prolonged exposure times and ex 
vivo studies showed no penetration of the NC in intact human skin or porcine ear skin.60,61 
1.5.3  Is their penetration behavior influenced by a barrier alteration using the IMQ-induced 
psoriasis-like mouse model? 
CMS penetration into a barrier disrupted skin is expected following published data showing 
increased NC penetration into tape-stripped ex vivo human skin and in an in vitro non-
melanoma skin cancer reconstructed skin model both resembling a barrier alteration.60  
1.5.4  Can CMS increase penetration of a cargo into intact murine skin compared to the 
topically applied cargo substance alone?  
CMS are expected to increase cargo penetration into in vivo murine skin in concordance with 
ex vivo data using human or porcine skin.60,61 
1.5.5  Can the IMQ-induced mouse model of psoriasis in BALB/c mice be used to evaluate a 
therapeutic surplus value of TAC-loaded CMS compared to commercial TAC ointment? 
The model is expected to be applicable since other groups have used the model in different 
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2.2 How effective is tacrolimus in the imiquimod - induced mouse model of 
psoriasis? 
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3 Concluding discussion and outlook 
3.1 Effect of core-multishell-nanocarrier on healthy or inflamed skin 
No adverse effects of CMS were observed locally in skin or in any distant organs tested after 
repeated topical application. Furthermore, in the IMQ-model with an altered skin barrier, no 
worsening of the inflammation was found in the CMS treated groups. (See paper 1 at 2.1) 
This confirms the hypothesis 1.5.1 (see 1.5 scientific questions and hypotheses), as expected, 
since toxicological prestudies in vitro in cell culture of fibroblasts and primary normal human 
keratinocytes did not report toxicity in the literature.4,62  
In addition to the in vivo data, even reanalysis in vitro using CMS doses higher than usually 
used in toxicological tests did not aggravate primary normal human keratinocytes. (See paper 
1 in 2.1) 
In vivo experiments are necessary for toxicity testing of promising NC at advanced stages of 
development. Advantages over in vitro tests include the possibility to test for possible toxic 
metabolites of NC derived by degradation by enzymes and pH on the skin surface as well as 
intracellular metabolization by immune cells. For CMS, potentially formed toxic metabolites 
could be aminated polyglycerols.67,68 This aspect might be missed in cell culture toxicology 
tests using only keratinocytes or tumor derived cell lines with changed cell biology due to their 
neoplastic transformation. 
Further evidence for good biocompatibility of these particles comes from the in vivo experiment 
by Radbruch et al. (2017), which was performed simultaneous within the CRC 1112. In this 
experiment no adverse effects were observed after topical application on healthy murine skin 
and an oxazolone-induced model for atopic dermatitis with a different pathogenesis4 compared 
to the psoriasis-like dermatitis model used in the study in this thesis (see Paper 1 at 2.1). In 
fact, not even repeated subcutaneous injection over 5 days led to local or systemic changes.4 
In contrast to the study in this thesis (see Paper 1 at 2.1) using BALB/c mice, Radbruch et al. 
(2017) used SKH1 mice. 
Both study protocols, of Radbruch et al. (2017) and Paper (see 2.1), with daily NC application 
on 5 consecutive days and subsequent sampling are not suitable to evaluate possible long-
term effects, or genotoxicity of CMS. Slow accumulation over time could lead to adverse effects 
not observed in this study. Even potential hypersensitivity reactions with newly formed 
antibodies or newly primed T lymphocytes could be missed due to the short time span between 
the first contact and a recontact after possible antibody production against the NC.7 This would 
have to be evaluated in further in vivo experiments with applications over a much longer period 
and analysis of further readout parameters.  
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Of note, this study was not primarily designed as toxicological study of CMS and the small 
number of mice per group limits its sensitivity to test for adverse effects. 
3.2 Local and systemic distribution of core-multishell-nanocarrier in intact 
and barrier disrupted skin 
Local penetration behavior of CMS in intact skin 
As expected following topical application of CMS on intact murine skin, no penetration into 
viable layers of the skin was observed; instead, the particles accumulated in the stratum 
corneum and superficial hair follicle infundibula. (See paper 1 at 2.1) 
In the literature, ex vivo studies also described no penetration of CMS into intact human skin 
or porcine ear skin.60,61 Ex vivo, CMS penetrated only after prolonged exposure times into 
human skin, as well as in a non-melanoma skin cancer reconstructed model.60 
This experiment was performed in Franz cells, common in ex vivo penetration studies, in which 
the skin is placed between a donator and acceptor chamber, which is filled with medium fluid. 
Over the incubation time of 24h, enabling CMS penetration, the skin was not only exposed to 
the applied CMS in the donator chamber but likely also overhydrated by the fluid of the 
acceptor compartment, leading to a swollen skin with a decreased barrier function. Therefore 
experiments in Franz cells, with long incubation times like 24h could lead to false positive 
penetration.69–71  
Lademann et al. published a pumping mechanism for solid NP of a certain size into the hair 
follicle by hair movement.72 It seems unlikely that the soft, deformable CMS would penetrate 
into hair follicles by this mechanism. Indeed, no particles were transported deep into the hair 
follicles despite massaging of the skin. Of course, evaluation of this mechanism is limited in 
this experiment, since the mice were depilated and thus lacked hairs reaching over the skin 
surface, which could have enabled the transport. However, the results are in concordance with 
the in vivo study by Radbruch et al. (2017) on hairless SKH1 mice, where sparse long hair is 
present, closer resembling human body skin, still no deep penetration was achieved.4 
Ex vivo experiments using porcine ear skin61, which is the model where the pumping 
mechanism was first described yielded similar results.20 Therefore, this mechanism seems 
unimportant for the CMS. 
Uptake of CMS into Langerhans cells has been reported in cell culture in vitro.73 Also in paper 
1, (see 2.1) a rare uptake of CMS by Langerhans cells is suggested. This was a rare 
observation of 4 colocalizations of a fluorescent signal with immunofluorescently marked 
Langerhans cells in 31 analyzed skin sections. For validation purposes of these signals, a 
fluorescence lifetime imaging microscopy (FLIM) examination could be helpful, particularly with 
the novel clustering technique used in paper 1. (See 2.1) Using FLIM, the fluorescent signal 
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could be identified with greater specificity and discriminated from autofluorescence or other 
artifacts, as the fluorescent tag indocarbocyanine (ICC) exhibits a unique fluorescent lifetime 
signature, which differs from fluorescing substances with the same emission spectrum. (For 
further details, see paper 1 at 2.1) The confocal character of FLIM also allows for the 
localization of the fluorescent signal to the intracellular compartment or the extracellular space 
next to the immunofluorescently stained Langerhans cell. For technical reasons, this was 
impossible for the slide in which the signals were observed. Even in a high number of examined 
consecutive slides, no further colocalizations of fluorescent signals with Langerhans cells in 
the viable epidermis could be found. To validate an uptake of topically applied CMS by 
Langerhans cells in vivo, more extensive studies have to be conducted to repeat the rare 
observation including for example FLIM analysis.  
 
Local penetration behavior of CMS in barrier altered skin models 
Surprisingly, the barrier alteration induced by IMQ in the psoriasis-like dermatitis model had 
no effect on the CMS penetration behavior. Even on ulcerated areas with serocellular crusts, 
no particles were found in deeper, viable layers of the skin. (See paper 1 at 2.1) 
In the oxazolone-induced atopic dermatitis model, representing a different barrier alteration by 
inflammation by Radbruch et al. (2017) showed similar results without CMS penetration in 
vivo.4  
This lack of penetration in both models is in contrast to the literature showing penetration into 
barrier altered non-melanoma skin cancer reconstructed models or ex vivo human skin with a 
barrier disruption by tape stripping.60 This highlights the importance of testing in different barrier 
altered models and the final proof in human skin diseases. Maybe the inflammatory skin 
models resemble barrier function of human inflammatory skin diseases like atopic dermatitis 
and psoriasis better than the in vitro and ex vivo models with a more artificial barrier disruption, 
which enabled NC penetration.60 In contrast to the decreased outside-inside barrier function 
by tape stripping, the various complex alterations in human psoriasis, including hyperkeratosis 
and epidermal thickening, do not have to sum up to an outside-inside barrier impairment but 
could also hinder the penetration of substances or particles.22 TEWL is a widely used 
parameter to measure a barrier dysfunction in clinic and research. It is based on increased 
permeability of water from inside to outside, which was elevated in both induced inflammatory 
mouse models. However, that does not necessarily have to reflect outside-inside barrier 
function.4 (See paper 1 at 2.1) Furthermore, the barrier function has to be evaluated for each 
substance or particle individually, even though predictions can be made regarding size, surface 
charge, and hydrophilicity.47 
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It must be kept in mind that the fluorescent ICC tag bound covalently to the CMS to make 
particle tracing in tissues possible could potentially influence the penetration behavior of the 
NC by steric changes.74 (See paper 1 at 2.1) Furthermore could a cargo drug loading into the 
NC change penetration behavior slightly. A cargo could influence steric properties of the NC 
regarding deformation or interplay with tissue. To evaluate these aspects additional in vitro 
studies with a more systemic approach comparing unloaded and loaded NC with different 
cargos in the same model are needed. In addition, common covalently bound fluorescent tags 
should be compared to less convenient but less influential radioactive tags75. However, these 
experiments exceed the scope of this work. 
The hypothesis that CMS penetrate into skin of the barrier altered IMQ-induced mouse model 
is not supported by these results. Further ex vivo studies using human psoriasis lesional skin 
could help to elucidate real penetration behavior in the planned field of application as a 
mechanism for targeted drug delivery. 
 
Systemic distribution of CMS 
Not surprisingly, considering that CMS do not penetrate into skin, CMS were not found in any 
draining lymph nodes or distant organs. (See paper 1 at 2.1) Distant organs screened included 
spleen, liver, lung, brain, thymus, heart, stomach, small and large intestine, mesenterial lymph 
nodes, pancreas, thyroid glands, adrenal glands, kidneys, testicles, and bone marrow. 
Radbruch et al. (2017) identified organs prone to CMS accumulation after simulated full 
penetration through skin by repeated subcutaneous injection of CMS.4 The particles were 
found in regional draining lymph nodes, in some glomeruli in the kidneys, in the liver, most 
likely in Kupffer cells, pulmonary alveolar macrophages, and spleen macrophages without any 
pathologic effects.4 The latter three belong to the mononuclear phagocyte system, filtering 
agents from circulating blood.4 
In the study in this thesis CMS were, as mentioned above, not found in these identified 
accumulation prone regions4 after topical application on intact or barrier altered skin. (See 
paper 1 at 2.1) 
3.3 Cargo delivery of core-multishell-nanocarrier 
Although CMS did not penetrate into viable skin layers themselves, they have the ability to 
increase the penetration of loaded cargo, nile red (NR), into intact murine skin compared to 
NR in a cream. (See paper 1 at 2.1)  
So the data support the hypothesis 1.5.4. 
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Literature also showed increased NR delivery by CMS into ex vivo porcine and human intact 
and tape stripped skin, as well as in in vitro human reconstructed skin.60,61  
The original concept (see also above at 1.4 Nanomaterial and Nanocarrier; Nanocarrier 
dermal drug delivery concept) of NC was that they would penetrate into skin and bring their 
loaded cargo along. In the deeper skin layers, this cargo would be released and binds to target 
structures or diffuses further to their side of action. Since CMS do not seem to penetrate skin 
but still deliver their cargo, the question arises how they do that. 
One hypothesis is that they penetrate with the cargo into the stratum corneum, from where 
they slowly release the cargo as a depot, holding the cargo longer in the stratum corneum 
increasing the time to penetrate deeper without being washed or rubbed off. A depot effect is 
to some extent also achieved by a cream or an ointment, accumulating in the stratum corneum 
lipids.76 
Another hypothesis is that CMS work as penetration enhancers by lowering the skin barrier 
function, which is mainly a property of the stratum corneum. The flexible, dendritic structure of 
CMS with long amphiphilic side chains forming the shells (also see Architecture of core-
multishell-nanocarrier at 1.4 Nanomaterial and Nanocarrier) could lead to intercalation in lipid 
bilayers in the stratum corneum. Thereby, the order of the extracellular stratum corneum lipids 
could be disturbed, potentially leading to a barrier disruption and increased cargo penetration.4 
Penetration enhancers are already used in pharmacology and in cream to achieve sufficient 
penetration of drugs. A prototype is dimethyl sulfoxide (DMSO), which has been widely studied 
and can lead to severe pathohistologically visible changes in skin.77 CMS do not lead to 
changes visible by light microscopy, which could be an advantage. Further experiments are 
needed to evaluate CMS mode of action, which is beyond the scope of this project. To 
elucidate the function of CMS as penetration enhancer an in vitro study could be conducted 
comparing loaded CMS to a mixture of unloaded CMS with free cargo and to the cargo 
substance alone. A comparison of CMS to standard penetration enhancers would be needed 
to show a surplus to already used penetration enhancers. 
The increased delivery of the loaded cargo has to be proven for real drugs loaded into the 
carriers. This could be done ex vivo, complemented in a second phase with an in vivo 
experiment using inflammation models to show a therapeutic surplus value of the CMS. 
Further studies should focus on the mode of action of CMS using different techniques. Several 
collaborations have been started to find changes in skin treated with CMS. TEM is used to 
visualize possible ultrastructural changes in the stratum corneum. In cooperation within the 
CRC Raman spectroscopy is used to study the order of lipids within the stratum corneum after 
CMS incubation. 
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3.4 Applicability of the imiquimod-induced psoriasis-like dermatitis model 
for in vivo testing of the topical, anti-inflammatory drug tacrolimus or 
nanocarrier for its delivery 
Choosing the right model for an experiment is essential to generate reliable results, but can be 
difficult if there is a lack of information in literature for either detailed characterization or 
comparison of models. Prediction or comparison of results with other studies elaborate similar 
hypotheses is limited by usage of model, mouse strains, protocols, and conducted readout.  
According to Nestle and Nickoloff the ideal model for psoriasis should fulfill the following 
criteria:78 1) epidermal changes including hyperproliferating keratinocytes with altered 
differentiation patterns, 2) papillomatosis, 3) intralesional inflammatory cells including T 
lymphocytes, dendritic cells, monocytes, macrophages, neutrophils, and mast cells, 4) pivotal 
functional role of T lymphocytes, 5) vascular changes characterized by tortuous capillaries and 
increased numbers of endothelial cells, and 6) response to anti-psoriatic drugs.  
The IMQ-induced psoriasis-like mouse-model fulfills criteria 1, 3, 4 and 5 but van der Fits et al. 
already stated that the response to anti-psoriatic drugs still has to be shown.36 
 
In paper 2, (see paper 2 at 2.2) topical treatment of the IMQ model with TAC was conducted 
using three different treatment protocols. In humans the effectiveness of TAC has been shown 
for facial psoriasis; in the plaque-type psoriasis it is hypothesized that poor skin penetration 
could inhibit topical efficacy.22 This poses a potential application for NC, if they are able to 
increase dermal cargo delivery.  
Topical TAC treatment once daily, starting on the fourth day of dermatitis induction, could not 
exert TAC-specific anti-inflammatory efficacy. (See paper 2 including supplemental material at 
2.2) 
Also in a preventative approach (see section “second treatment protocol” in Paper 2 at 2.2) 
with treatment starting on the first day of dermatitis induction, no TAC-specific anti-
inflammatory efficacy was observed.  
There is a conflict to reported successful treatment of the IMQ model with TAC.40,63–66 On one 
hand, some induced the psoriasis-like dermatitis in different mouse strains or used slightly 
different protocols, which might have an impact on the experimental outcome, complicating a 
direct comparison of results.64,79 On the other hand, some studies were missing vehicle 
controls only comparing to untreated controls63–66 or showed only minimal improvement of 
rather subjective clinical scores compared to vehicle controls.40 In those cases, drug unspecific 
skincare effects of the vehicle or random individual variations of dermatitis induction or 
maintenance severity favoring TAC groups might have been over interpreted as TAC-specific 
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effects. This could point towards the possibility that TAC might not be effective in the IMQ 
model at least using BALB/c mice. 
 
Hypotheses why TAC-specific effects in the IMQ model could not been shown here include the 
following (see paper 2 at 2.2): 
The barrier alteration of the model or application regimes could have impaired TAC penetration 
in effective amounts into the skin. There are no data on effective amounts extractable from 
skin layers in successfully treated human psoriasis or murine models of psoriasis. 
Nonetheless, after topical application of commercially available ointment with the highest TAC 
concentration in the second treatment protocol, a TAC concentration of 300 ng/cm² in the 
dermis could be achieved. This is in the same magnitude as TAC extracted from skin of 
successfully treated humans with atopic dermatitis.80 Therefore, it can be assumed that TAC 
penetration was sufficient to its site of action, the lymphocytes in the dermis.81  
Furthermore, the drug could target pathways not pivotal for the phenotype development in the 
IMQ model.  
TAC is a calcineurin inhibitor.38 Its immunosuppressive effect is due to interaction of several 
pathways leading to decreased transcription of cytokines important for T cell function. By 
inhibiting the calmodulin-dependent phosphatase calcineurin, nuclear translocation of nuclear 
factor of activated T lymphocytes (NFAT) and nuclear factor kappa-light-chain-enhancer of 
activated B-cells (NFkB) is blocked and transcription of IL 2 but also IL 4, 10, and 17, TNF α, 
and IFN y is decreased. Lack of these cytokines influences T helper and T killer lymphocyte 
differentiation, activation and survival. TAC also blocks the activation of mitogen-activated 
protein (MAP)-kinase-kinase-kinases like MAP3K11 and MAP3K7, leading to decreased c-Jun 
N-terminal Kinases (JNK) and p38 activation, which modulate activator protein (AP) 1 family 
related gene expression. TAC also inhibits IL-2-dependent T cell proliferation via increasing 
transforming growth factor β1 (TGFβ1) expression.39 
The IMQ-induced psoriasis-like dermatitis is a primarily T lymphocyte driven immune response 
due to TLR 7 and 8 activation. (See also Model used in this study: Imiquimod–induced 
psoriasis-like dermatitis at 1.2 Psoriasis – a common inflammatory skin disease)  
TLR 7 and 8 are pattern recognition receptors expressed in endosomes in plasmocytoid 
dendritic cells, monocytes, macrophages, B lymphocytes and eosinophils. Their activation 
signals via the adaptor protein myeloid differentiation primary response 88 (MyD88) and 
transcription factors like NFkB and activator protein 1 (AP-1) family members are activated 
leading to increased expression of pro-inflammatory cytokines and chemokines including IFN 
α and β. AP-1 is activated via MAP-kinase signaling pathway including p38.82 Some pathways, 
which activate NFkB and AP-1 via p38 can be blocked by TAC.39 
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IMQ induces plasmocytoid dendritic cell maturation,83 T helper 1 lymphocyte response84 and 
inflammatory cytokine production by keratinocytes.36,85,86  
TLR-independent effects include adenosine receptor signaling interference leading to similar 
inflammatory effects.87 In this pathway, calcineurin is involved, which is inhibited by TAC. 
IL 22, IL 36, and the IL 23-IL 17 pathways play pivotal roles in the IMQ-induced phenotype 
development.26,36 IL 17A is predominantly produced by different T lymphocytes including T 
helper 17 lymphocytes.88 It can also be produced by neutrophils, but since lymphocytes are 
the main component of leukocyte infiltration in this model this seems less important.89 IL 17 
production via NFAT is also blocked by calcineurin inhibition of TAC. 
Since IMQ is T lymphocyte driven and TAC interferes with proper T lymphocyte inflammatory 
responses, it suggests itself that TAC would interfere with dermatitis induction in this mouse 
model. 
Finally, it is also conceivable that the TAC efficacy on IMQ-induced dermatitis is mouse strain 
dependent. In this study, BALB/c mice were used, since van der Fits et al. introduced the IMQ-
induced mouse model in this strain and it was further used in literature for this model.36 Some 
studies reporting TAC specific effects induced the IMQ model in C57BL/6 mice.64,79 Mouse 
strain dependent differences in experimental outcome are not unusual.79 Both C57BL/6 and 
BALB/c mice are inbred strains with a very narrow, yet different genepool background. 
Different responses of the immune system have been described.79 In contrast to these strains, 
the IMQ-model was not inducible at all in the hairless, but immunocompetent and therefore for 
dermatology studies convenient SKH1 mouse strain (see paper 2 at 2.2). This strongly 
suggests a high dependence on the right genetic background.  
 
To evaluate why this model might not be treatable with TAC or why it might not be possible in 
this mouse strain is beyond the scope of this work but the elucidation could be valuable for 
research. Further elucidation could serve important information about the inflammatory 
pathways of this model or their dysfunction in this mouse strain, both further identifying 
limitations and possible applications for evaluation of specific questions. This could even help 
to understand pathogenesis of human psoriasis better and possibly result in new targets for 
clinical treatment.  
However, the IMQ-induced psoriasis like dermatitis model was not applicable to evaluate a 
therapeutic surplus value of TAC-loaded CMS over TAC ointment, at least using these 
protocols in BALB/c mice. 
 
In contrast to the first two treatment protocols just discussed, in the third treatment protocol 
(see paper 2 at 2.2) test substances were applied twice daily leading to no or only minimal 
psoriasis-like phenotype expression. Twice daily, topical test substance application somehow 
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disturbed the model induction via topical IMQ application in all groups. This observation was 
independent of the type of test substance, including hydrogel and ointment without active 
compounds and TAC ointment. Therefore, the absence of skin inflammation induction cannot 
depict a TAC-specific anti-inflammatory effect.  
A lack of model induction could most conveniently be explained by lack of IMQ penetration 
due to interaction with the other applied formulations. This could especially arise by two 
mechanisms:  
a) If a formulation is applied before application of IMQ, it could physically hinder IMQ 
penetration into the skin. For example, application of ointment could lead to deposition of 
additional lipids in the stratum corneum and thus increase hydrophobicity of this layer. 
Remnants of hydrogel could also remain in the stratum corneum and hinder IMQ penetration. 
However, dermatitis evolved in the first treatment protocol with test substance application 
approximately 4 h before application of IMQ. This is the same period of time between the first 
test substance application and the IMQ application in the third protocol, thus this alone cannot 
explain the lack of model induction. 
b) The amount of time IMQ remained on the skin could be too short for sufficient penetration 
of IMQ. This could happen if a test substance is applied after IMQ, because removal of 
remaining IMQ cream from the skin surface was needed prior to every application of test 
substance. However, dermatitis also evolved in the second treatment protocol with removal of 
IMQ cream and test substance application approximately 2 h after IMQ application. This is the 
same period of time between the IMQ application and the second test substance application 
in the third protocol, thus this alone cannot explain the lack of model induction. 
Only in the third treatment protocol, being a mixture of the first two protocols with IMQ 
application 4 h after and 2 h before test substance application, IMQ effects were inhibited.  
It is suspected that the additive effect of test substance remnants, hindering penetration, and 
premature removal of IMQ from the skin prevented model induction even if neither effect alone 
prevented it.  
 
Another possible explanation would be that IMQ did penetrate sufficiently, but unspecific skin 
care effects of any hydrogel or ointment application block the phenotype expression. Skin care 
effects could cause a protection of the skin barrier. A disturbance of the skin barrier possibly 
is a necessary secondary, worsening aspect of phenotype development.  
Whichever explanation may reflect the truth, the third protocol, as conducted, is unsuitable to 
test any applied substances for anti-inflammatory efficacy or penetration behavior in altered 
skin barrier (see paper 2 at 2.2). Perhaps a longer time period between the IMQ and the second 
test substance application could improve model induction, but this is speculative. 
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3.5 Conclusions 
NC have to fulfill three major requirements for the usage for drug delivery in inflammatory skin 
diseases: 1) they have to be biocompatible, 2) they need to improve drug delivery to the site 
of action and 3) this has to lead to a therapeutic surplus value over conventional drug 
formulation.   
To conclude, the CMS themselves do not penetrate into murine skin, intact or inflamed, and 
do not show any adverse effects. Thus, CMS seem to fulfill requirement number 1, but long-
term toxicological studies in larger numbers of individuals and clinical trials have to 
complement these results. 
The increased cargo delivery into skin, shown for the model drug NR, is promising for the 
further development as NC. Nevertheless, superior cargo delivery has to be tested for 
individual pharmacologically active drugs like TAC to fulfill the second requirement.  
A therapeutic surplus value still has to be shown for the usage of CMS compared to commercial 
formulations of the drugs.  
The IMQ-induced psoriasis-like mouse model seems not applicable for that task, since no TAC-
specific drug efficacy could be shown in BALB/c mice. 
In summary, the CMS are promising candidates for a further development regarding 
biocompatibility and improved drug delivery but a therapeutic surplus value needs to be shown. 
 
Further studies should be conducted to uncover the cargo delivery mechanism of CMS. This 
could improve refinement or invention of new NC or help to find other fields of application for 
the CMS.  
 
In addition to the findings regarding NC, three important observations were made: 
a) TAC may not be effective in the IMQ-induced psoriasis-like mouse model in BALB/c mice. 
b) Suitable vehicle controls, often omitted in previous reports are imperative, because 
vehicles may have a strong influence on the model. 
c) SKH 1 hairless mice should not be used for the IMQ model, since it is not inducible in this 
strain following standard protocols. 
Why the psoriasis-like dermatitis could not be alleviated with TAC as well as why the model 
could not be induced in SKH1 mice remains unclear. Further studies to elucidate this could be 
beneficial to gain more insights into the pathogenesis of the model or the immune system of 
the mouse strains giving new applications or limitations for both, or possibly help to better 
understand the pathogenesis of human psoriasis leading to new therapeutic targets.  
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4 Summary 
Core-Multishell-Nanocarrier for Topical Drug Delivery in a Psoriasis Mouse Model  
Jeanette HANNAH Charlotte Pischon  
Psoriasis is a common, chronic, multifactorial, human skin disease, characterized by well-
demarcated, raised, erythematous plaques covered with silvery scales.1,3 It is incurable and 
often requires long period therapy with immunomodulatory drugs, which can lead to side 
effects, especially when administered systemically in more severe cases.3 Nanocarrier are 
engineered particles of a size between 1 nm and 100 nm at least in one dimension. For skin, 
nanocarrier are designed to increase the delivery of drugs or genes through the skin barrier, 
target the drug to a specific layer, or prevent systemic distribution and thereby negative effects 
in distant organs. 
In paper 1 of this thesis, core-multishell nanocarrier were investigated topically on mouse skin 
in vivo. This nanocarrier had been designed like a uni-molecular micelle4 with a hydrophilic 
core, an inner lipophilic shell, and an outer hydrophilic shell to make the particle water-soluble 
and provide space for drugs of different lipophilicity to be loaded into the core or the inner shell. 
Originally, they had been thought to penetrate through the skin and release their cargo at its 
site of action. Literature already had stated that several nanocarrier or nanoparticles do not 
penetrate into skin, whereas others do and even others penetrate only through a disrupted 
barrier.19,21 The core-multishell nanocarrier used here did not penetrate into viable layers of 
intact or inflamed skin using the imiquimod-induced psoriasis model in BALB/c mice. Instead, 
they accumulated in the stratum corneum. Previous in vitro data had shown core-multishell 
nanocarrier penetration into tape stripped human skin ex vivo.60 The accumulation in the 
stratum corneum could possibly be used as a depot for a retarded and prolonged release of 
drugs. 
Parallel to the penetration study no adverse effects were observed locally or systemically. This 
is in concordance with literature also stating no negative effects even after repeated 
subcutaneous injection of this carrier.4 
The topical application of nile red loaded core-multishell nanocarrier revealed superior cargo 
delivery into the viable epidermis compared to a nile red cream. Further elucidation of the 
mechanism by which the core-multishell nanocarrier enhances the penetration of nile red, and 
proof of concept for real drugs are needed. However, the core-multishell nanocarrier remains 
as a promising candidate for further development for therapy of skin diseases including testing 
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of a therapeutic surplus value of drug loaded nanocarrier compared to commercial topical drug 
formulations. 
No tacrolimus-specific anti-inflammatory effects could be shown in the imiquimod-induced 
psoriasis-like dermatitis model using BALB/c mice, despite penetration of the drug into the 
dermis.  
Further research is needed to elucidate the reason for the lack of that efficacy and the conflict 
to literature and the dependence of tacrolimus efficacy in this model on mouse strains.40,63–66 
However, this model was not applicable to evaluate therapeutic superiority of core-multishell 
nanocarrier for tacrolimus delivery compared to tacrolimus ointment. 
The importance of choosing an appropriate model for the specific question, using multiple 
objective readout parameters to avoid over-interpretation of small variations, and testing 




Core-Multishell-Nanocarrier für den topischen Wirkstofftransport  
in einem Psoriasis Mausmodell 
Jeanette HANNAH Charlotte Pischon  
Psoriasis ist eine häufige, chronische, multifaktorielle Hauterkrankung des Menschen, welche 
durch scharf begrenzte, erhabene, erythematöse Plaques, die mit silbrigen Schuppen bedeckt 
sind, charakterisiert ist.1,3 Psoriasis ist unheilbar und oft ist eine Langzeittherapie mit 
immunmodulatorischen Medikamenten nötig, welche vor allem in schweren Fällen bei 
systemischer Applikation zu unerwünschten Nebenwirkungen führen können.3 Nanocarrier 
sind synthetische Partikel von einer Größe zwischen 1 nm und 100 nm in mindestens einer 
Dimension. Für die Anwendung auf der Haut wurden Nanocarrier entwickelt um, Wirkstoffe 
oder Gene vermehrt durch die Hautbarriere zu transportieren, bestimmte Schichten 
anzusteuern oder eine systemische Verteilung des Wirkstoffes, und dabei Nebenwirkungen in 
Organen, zu verhindern.  
In der ersten Publikation aus dieser Dissertation wurden Core-Multishell Nanocarrier in vivo 
topisch auf Maushaut getestet. Dieser Nanocarrier wurde in Analogie zu einer ein-molekularen 
Mizelle4 mit einem hydrophilen Kern, einer lipophilen inneren Schale und einer hydrophilen 
äußeren Schale entwickelt, um den Partikel wasserlöslich zu machen und Wirkstoffe 
verschiedener Lipophilität im Kern und der inneren Schale transportieren zu können. 
Ursprünglich sollten die Nanocarrier in die Haut eindringen und ihre Ladung an dessen 
Wirkungsort freigeben. In der Literatur ist bereits zu finden, dass verschiedene Nanocarrier 
und Nanopartikel nicht in Haut eindringen, wobei andere dieses tun und wieder andere nur in 
barrieregestörte Haut eindringen.19,21 Die hier genutzten Core-Multishell Nanocarrier drangen 
nicht in vitale Hautschichten von gesunder oder entzündeter Haut des Imiquimod induzierten 
Psoriasis ähnlichen Mausmodels in BALB/c Mäusen ein, sondern akkumulierten im Stratum 
corneum. Vorangegangene in vitro Studien hatten bereits ein Eindringen von Core-Multishell 
Nanocarriern in humane Haut ex vivo nach Tape stripping gezeigt.60 Diese Ansammlung der 
Nanocarrier im Stratum corneum könnte möglicherweise als Depot für eine retardierte und 
damit verlängerte Wirkstofffreisetzung genutzt werden. 
Gleichzeitig konnten in den Penetrationsexperimenten keine lokalen oder systemischen 
negativen Effekte der Core-Multishell Nanocarrier beobachtet werden. Das steht in Einklang 
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mit der vorhandenen Literatur, welche sogar nach wiederholter subkutaner Injektion dieser 
Nanocarrier keine negativen Effekte beschreibt.4 
Die topische Applikation von mit Nilrot beladenen Core-Multishell Nanocarriern zeigte einen 
vermehrten Ladungstransport in die vitale Epidermis im Vergleich zu Nilrot in einer Crème. 
Weitere Aufklärung des Mechanismus, mit dem die Core-Multishell Nanocarrier das 
Eindringen von Nilrot verstärken, und ein Wirksamkeitsnachweis für echte Wirkstoffe 
benötigen weiterführende Untersuchungen. Allerdings bleiben die Core-Multishell Nanocarrier 
vielversprechende Kandidaten für die Weiterentwicklung der Nanocarrier zur Therapie von 
Hauterkrankungen einschließlich des Nachweises eines Therapievorteils wirkstoffbeladener 
Core-Multishell Nanocarrier gegenüber kommerziellen topischen Formulierungen.  
Es konnten keine Tacrolimus spezifischen antiinflammatorischen Effekte im Psoriasis 
ähnlichen, Imiquimod induzierten Dermatitis Modell in BALB/c Mäusen gezeigt werden, trotz 
Eindringen des Wirkstoffes in die Dermis.  
Weitergehende Untersuchungen sind notwendig, um den Grund für die fehlende Effizienz, 
dessen Widerspruch mit vorhandener Literatur und eine mögliche Abhängigkeit der Tacrolimus 
Wirksamkeit in diesem Modell von Mausstämmen zu erforschen.40,63–66 Unabhängig davon ist 
das Imiquimod induzierte Psoriasis Modell mit den hier verwendeten Protokollen in BALB/c 
Mäusen nicht zur Testung eines möglichen Therapievorteils von Core-Multishell Nanocarriern 
zum Tacrolimus Transport gegen Tacrolimussalbe geeignet. 
 
Des Weiteren wird die Wichtigkeit betont, ein passendes Modell zur Forschungsfragestellung 
auszuwählen und mehrere objektive Parameter auszuwerten, um Überinterpretation von 
kleinen Schwankungen gegen alle notwendigen Kontrollgruppen inklusive Vehikelkontrollen 
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